Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 759

1.

Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.

Hsu WH, Zhao X, Zhu J, Kim IK, Rao G, McCutcheon J, Hsu ST, Teicher B, Kallakury B, Dowlati A, Zhang YW, Giaccone G.

J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108-X. doi: 10.1016/j.jtho.2019.01.028. [Epub ahead of print]

PMID:
30771522
2.

Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.

Zhao X, Kallakury B, Chahine JJ, Hartmann D, Zhang Y, Chen Y, Zhang H, Zhang B, Wang C, Giaccone G.

J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30096-6. doi: 10.1016/j.jtho.2019.01.019. [Epub ahead of print]

PMID:
30735815
3.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Levy BP, Giaccone G, Besse B, Felip E, Garassino MC, Domine Gomez M, Garrido P, Piperdi B, Ponce-Aix S, Menezes D, MacBeth KJ, Risueño A, Slepetis R, Wu X, Fandi A, Paz-Ares L.

Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.

PMID:
30654297
4.

Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene.

Di Fede G, Catania M, Atzori C, Moda F, Pasquali C, Indaco A, Grisoli M, Zuffi M, Guaita MC, Testi R, Taraglio S, Sessa M, Gusmaroli G, Spinelli M, Salzano G, Legname G, Tarletti R, Godi L, Pocchiari M, Tagliavini F, Imperiale D, Giaccone G.

Acta Neuropathol Commun. 2019 Jan 3;7(1):1. doi: 10.1186/s40478-018-0656-4.

5.

Neuro-Behçet's disease presenting as an isolated progressive cognitive and behavioral syndrome.

Saracino D, Allegorico L, Barbarulo AM, Pollo B, Giaccone G, D'Amico A, D'Incerti L, Bugiani O, Di Iorio G, Sampaolo S, Melone MAB.

Neurocase. 2018 Dec 25:1-4. doi: 10.1080/13554794.2018.1561898. [Epub ahead of print]

PMID:
30583716
6.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA.

PLoS One. 2018 Nov 27;13(11):e0208097. doi: 10.1371/journal.pone.0208097. eCollection 2018.

7.

Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

Vietsch EE, Graham GT, McCutcheon JN, Javaid A, Giaccone G, Marshall JL, Wellstein A.

Cancer Genet. 2018 Dec;228-229:131-142. doi: 10.1016/j.cancergen.2018.11.001. Epub 2018 Nov 9.

PMID:
30447903
8.

Tau Mutations as a Novel Risk Factor for Cancer-Response.

Rossi G, Redaelli V, Perego P, Ferrari R, Giaccone G, Tagliavini F.

Cancer Res. 2018 Nov 15;78(22):6525. doi: 10.1158/0008-5472.CAN-18-2730. Epub 2018 Oct 29. No abstract available.

PMID:
30373808
9.

What Can We Learn From the French Experience in Systemic Treatment of Thymic Epithelial Tumors?

Giaccone G.

J Thorac Oncol. 2018 Nov;13(11):1623-1624. doi: 10.1016/j.jtho.2018.09.009. No abstract available.

PMID:
30368408
10.

Understanding molecular diagnostic technology in oncology through the lens of lung cancer.

Jonna S, Giaccone G, Subramaniam DS.

Discov Med. 2018 Aug;26(141):21-29. Review.

11.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies .

Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398.

PMID:
30202892
12.

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.

Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, Zhang YW, Giaccone G.

Oncogene. 2019 Jan;38(2):180-193. doi: 10.1038/s41388-018-0429-3. Epub 2018 Aug 9.

PMID:
30093630
13.

Synthetic Prion Selection and Adaptation.

Bistaffa E, Moda F, Virgilio T, Campagnani I, De Luca CMG, Rossi M, Salzano G, Giaccone G, Tagliavini F, Legname G.

Mol Neurobiol. 2018 Aug 3. doi: 10.1007/s12035-018-1279-2. [Epub ahead of print]

PMID:
30074230
14.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J.

Eur J Cancer. 2018 Sep;101:114-122. doi: 10.1016/j.ejca.2018.06.033. Epub 2018 Jul 24.

PMID:
30053670
15.

Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges.

Abu-Rumeileh S, Redaelli V, Baiardi S, Mackenzie G, Windl O, Ritchie DL, Didato G, Hernandez-Vara J, Rossi M, Capellari S, Imperiale D, Rizzone MG, Belotti A, Sorbi S, Rozemuller AJM, Cortelli P, Gelpi E, Will RG, Zerr I, Giaccone G, Parchi P.

Ann Neurol. 2018 Sep;84(3):347-360. doi: 10.1002/ana.25300. Epub 2018 Aug 31.

PMID:
30048013
16.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

17.

Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.

Rao G, Kim IK, Conforti F, Liu J, Zhang YW, Giaccone G.

Eur J Cancer. 2018 Aug;99:37-48. doi: 10.1016/j.ejca.2018.05.013. Epub 2018 Jun 11.

PMID:
29902613
18.

Tau Mutations Serve as a Novel Risk Factor for Cancer.

Rossi G, Redaelli V, Contiero P, Fabiano S, Tagliabue G, Perego P, Benussi L, Bruni AC, Filippini G, Farinotti M, Giaccone G, Buiatiotis S, Manzoni C, Ferrari R, Tagliavini F.

Cancer Res. 2018 Jul 1;78(13):3731-3739. doi: 10.1158/0008-5472.CAN-17-3175. Epub 2018 May 24.

19.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

20.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Sep;19(5):e567-e574. doi: 10.1016/j.cllc.2018.03.016. Epub 2018 Mar 23.

PMID:
29681434
21.

Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases.

Legname G, Virgilio T, Bistaffa E, De Luca CMG, Catania M, Zago P, Isopi E, Campagnani I, Tagliavini F, Giaccone G, Moda F.

Prion. 2018 Mar 4;12(2):127-137. doi: 10.1080/19336896.2018.1464367. Epub 2018 May 18.

PMID:
29676205
22.

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML.

Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.

23.

Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline.

Moeller B, Balagamwala EH, Chen A, Creach KM, Giaccone G, Koshy M, Zaky S, Rodrigues G.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):245-250. doi: 10.1016/j.prro.2018.02.009. Epub 2018 Apr 4.

PMID:
29625898
24.

C-MET inhibitors for advanced non-small cell lung cancer.

Pasquini G, Giaccone G.

Expert Opin Investig Drugs. 2018 Apr;27(4):363-375. doi: 10.1080/13543784.2018.1462336. Epub 2018 Apr 11. Review.

PMID:
29621416
25.

Precision oncology in non-small-cell lung cancer: opportunities and challenges.

Kim C, Giaccone G.

Nat Rev Clin Oncol. 2018 Jun;15(6):348-349. doi: 10.1038/s41571-018-0008-0. No abstract available.

PMID:
29599475
26.

A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer.

Subramaniam DS, Liu SV, Crawford J, Kramer J, Thompson J, Wang H, Giaccone G.

Front Oncol. 2018 Mar 12;8:64. doi: 10.3389/fonc.2018.00064. eCollection 2018.

27.

Frontotemporal Dementia and Chorea Associated with a Compound Heterozygous TREM2 Mutation.

Redaelli V, Salsano E, Colleoni L, Corbetta P, Tringali G, Del Sole A, Giaccone G, Rossi G.

J Alzheimers Dis. 2018;63(1):195-201. doi: 10.3233/JAD-180018.

PMID:
29578490
28.

Molecular subtypes of Alzheimer's disease.

Di Fede G, Catania M, Maderna E, Ghidoni R, Benussi L, Tonoli E, Giaccone G, Moda F, Paterlini A, Campagnani I, Sorrentino S, Colombo L, Kubis A, Bistaffa E, Ghetti B, Tagliavini F.

Sci Rep. 2018 Feb 19;8(1):3269. doi: 10.1038/s41598-018-21641-1.

29.

The Integrated Genomic Landscape of Thymic Epithelial Tumors.

Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC; Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Ströbel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJ.

Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

30.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
31.

High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.

Park KS, Moon YW, Raffeld M, Lee DH, Wang Y, Giaccone G.

Lung Cancer. 2018 Feb;116:38-45. doi: 10.1016/j.lungcan.2017.12.010. Epub 2017 Dec 15.

PMID:
29413049
32.

Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases.

Vanni S, Zattoni M, Moda F, Giaccone G, Tagliavini F, Haïk S, Deslys JP, Zanusso G, Ironside JW, Carmona M, Ferrer I, Kovacs GG, Legname G.

Front Neurosci. 2018 Jan 22;12:8. doi: 10.3389/fnins.2018.00008. eCollection 2018.

33.

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.

Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT, Subramaniam DS, Liu SV, Kaplan IM, McCutcheon JN.

Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.

PMID:
29395863
34.

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.

PMID:
29392450
35.

In Situ Tissue Labeling of Cerebral Amyloid Using HIV-Related Tat Peptide.

Maderna E, Colombo L, Cagnotto A, Di Fede G, Indaco A, Tagliavini F, Salmona M, Giaccone G.

Mol Neurobiol. 2018 Aug;55(8):6834-6840. doi: 10.1007/s12035-018-0870-x. Epub 2018 Jan 19.

PMID:
29349578
36.

Iatrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study.

Cali I, Cohen ML, Haik S, Parchi P, Giaccone G, Collins SJ, Kofskey D, Wang H, McLean CA, Brandel JP, Privat N, Sazdovitch V, Duyckaerts C, Kitamoto T, Belay ED, Maddox RA, Tagliavini F, Pocchiari M, Leschek E, Appleby BS, Safar JG, Schonberger LB, Gambetti P.

Acta Neuropathol Commun. 2018 Jan 8;6(1):5. doi: 10.1186/s40478-017-0503-z.

37.

MEK inhibitors under development for treatment of non-small-cell lung cancer.

Kim C, Giaccone G.

Expert Opin Investig Drugs. 2018 Jan;27(1):17-30. doi: 10.1080/13543784.2018.1415324. Epub 2017 Dec 13. Review.

PMID:
29216787
38.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G.

Lung Cancer. 2017 Oct;112:195-199. doi: 10.1016/j.lungcan.2017.08.017. Epub 2017 Aug 23.

PMID:
29191595
39.

Translational Research in Alzheimer's and Prion Diseases.

Di Fede G, Giaccone G, Salmona M, Tagliavini F.

J Alzheimers Dis. 2018;62(3):1247-1259. doi: 10.3233/JAD-170770.

40.

Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

Vietsch EE, Graham GT, McCutcheon JN, Javaid A, Giaccone G, Marshall JL, Wellstein A.

Cancer Genet. 2017 Dec;218-219:39-50. doi: 10.1016/j.cancergen.2017.08.006. Epub 2017 Sep 14.

41.

Differential overexpression of SERPINA3 in human prion diseases.

Vanni S, Moda F, Zattoni M, Bistaffa E, De Cecco E, Rossi M, Giaccone G, Tagliavini F, Haïk S, Deslys JP, Zanusso G, Ironside JW, Ferrer I, Kovacs GG, Legname G.

Sci Rep. 2017 Nov 15;7(1):15637. doi: 10.1038/s41598-017-15778-8.

42.

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Zhao X, McCutcheon JN, Kallakury B, Chahine JJ, Pratt D, Raffeld M, Chen Y, Wang C, Giaccone G.

J Thorac Oncol. 2018 Feb;13(2):237-245. doi: 10.1016/j.jtho.2017.10.010. Epub 2017 Oct 31.

43.

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

Smith TJ, Hanna N, Johnson D, Baker S Jr, Biermann WA, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Tashbar J, Temin S, Masters G.

J Oncol Pract. 2017 Dec;13(12):780-783. doi: 10.1200/JOP.2017.027367. Epub 2017 Oct 5. No abstract available.

PMID:
28981389
44.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR.

Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27.

45.

High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions.

Franceschini A, Baiardi S, Hughson AG, McKenzie N, Moda F, Rossi M, Capellari S, Green A, Giaccone G, Caughey B, Parchi P.

Sci Rep. 2017 Sep 6;7(1):10655. doi: 10.1038/s41598-017-10922-w.

46.

Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Conforti F, Zhang X, Rao G, De Pas T, Yonemori Y, Rodriguez JA, McCutcheon JN, Rahhal R, Alberobello AT, Wang Y, Zhang YW, Guha U, Giaccone G.

Cancer Res. 2017 Oct 15;77(20):5614-5627. doi: 10.1158/0008-5472.CAN-17-1323. Epub 2017 Aug 17.

47.

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, Riely GJ, Schiller JH, Schneider BJ, Smith TJ, Tashbar J, Biermann WA, Masters G.

J Clin Oncol. 2017 Oct 20;35(30):3484-3515. doi: 10.1200/JCO.2017.74.6065. Epub 2017 Aug 14.

PMID:
28806116
48.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.

Sci Rep. 2017 Aug 1;7(1):7066. doi: 10.1038/s41598-017-06128-9.

49.

An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.

Fu Y, Silverstein S, McCutcheon JN, Dyba M, Nath RG, Aggarwal M, Coia H, Bai A, Pan J, Jiang J, Kallakury B, Wang H, Zhang YW, Giaccone G, He AR, Chung FL.

Hepatology. 2018 Jan;67(1):159-170. doi: 10.1002/hep.29380. Epub 2017 Nov 13.

50.

Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type).

Baiardi S, Magherini A, Capellari S, Redaelli V, Ladogana A, Rossi M, Tagliavini F, Pocchiari M, Giaccone G, Parchi P.

J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):764-772. doi: 10.1136/jnnp-2017-315942. Epub 2017 Jul 1.

PMID:
28668775

Supplemental Content

Loading ...
Support Center